×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Implementation of GDUFA: Progress and Expectations
Session Chair(s)
Kathleen Uhl, MD
Director, Office of Generic Drugs, CDER
FDA, United States
With the implementation of The Generic Drug User Fee Amendments (GDUFA) on October 1, 2012, new processes and expectations for both the generic industry and the FDA were also implemented. This session will discuss the progress in implementation of GDUFA.
Learning Objective : Describe the changes in the abbreviated new drug application (ANDA) review process that have been made; Describe the the communication and submission expections for ANDA applications associated with GDUFA.
Speaker(s)
Overview of Significant GDUFA-Related Policy Changes
Keith J. Flanagan
FDA, United States
Director, Office of New Drug Policy, CDER
GDUFA Regulatory Science: Implementation Update
Robert A. Lionberger, PhD
FDA, United States
Director, Office of Research and Standards, Office of Generic Drugs, CDER
Overview of GDUFA: Changes and Progress
Kathleen Uhl, MD
FDA, United States
Director, Office of Generic Drugs, CDER
Have an account?